Table 2.
Characteristics of Febrile Neutropenia Episodesa
| Characteristic | N (%) | ||
|---|---|---|---|
| Pre- Intervention | Post- Intervention | ||
| (2009–2011) | (2013–2015) | P Valueb | |
| n = 697 FN Episodes | n = 691 FN Episodes | ||
| Risk classification | .91 | ||
| Standard | 357 (51) | 356 (52) | … |
| High | 340 (49) | 335 (48) | … |
| Sepsis, or septic shock | 55 (16) | 42 (13) | … |
| Neutropenic enterocolitis (typhlitis) | 8 (2) | 7 (2) | … |
| ALL in all phases except continuation | 223 (66) | 201 (60) | … |
| AML in all phases except maintenance | 47 (14) | 53 (16) | … |
| Relapsed AML, ALL in any phase of therapy | 45 (13) | 60 (18) | … |
| Down syndrome | 16 (5) | 12 (4) | … |
| Lymphoma: advanced-stage NHL, recurrent NHL, or recurrent Hodgkin disease with intensively myelosuppressive chemotherapy | 37 (11) | 48 (14) | … |
| Infection during episode | .02 | ||
| No infection | 499 (72) | 532 (77) | … |
| Infection | 198 (28) | 159 (23) | … |
| Clinically suspected | 93 (47) | 82 (52) | .58 |
| Microbiologically documented | 92 (46) | 66 (42) | … |
| Both clinically and microbiologically documented | 13 (7) | 11 (7) | … |
| Infection typec | … | ||
| Bacteremia | 63 (32) | 41 (26) | … |
| Skin/soft tissue | 55 (28) | 36 (23) | … |
| Other | 23 (12) | 23 (14) | … |
| Clostridiodies difficile infection | 22 (11) | 29 (18) | … |
| Community-acquired pneumonia | 19 (10) | 16 (10) | … |
| Urinary tract infection | 7 (4) | 3 (2) | … |
| Typhlitis | 5 (3) | 5 (3) | … |
| Pharyngitis | 3 (1) | 2 (1) | … |
| Otitis media | 2 (1) | 2 (1) | … |
| Ventilator-associated pneumonia | 0 (0) | 3 (2) | … |
| Sinusitis | 0 (0) | 1 (1) | … |
| Osteomyelitis | 0 (0) | 2 (1) | … |
| Multiple infections | 74 (37) | 75 (47) | … |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; FN, febrile, neutropenia; NHL, non-Hodgkin lymphoma.
aN = 1388 episodes.
b P value from the χ2 test for categorical variables testing for difference in distribution by period.
cNot mutually exclusive.